In this journal, features on the current regulatory positions on nitrosamine impurities, how investing in off-patent medicines can help drive innovation and why new regulations could lead to a biosimilar boom in the UK. Other articles include an exploration of the challenges in developing and delivering lipid nanoparticle mRNA-based vaccines,…
List view / Grid view
Nuclear magnetic resonance (NMR)
17 May 2021 | By Bruker Biospin Group
In this on-demand webinar, Kathleen Farley (Senior Principal Scientist, R&D, Pfizer Inc) describes how nuclear magnetic resonance (NMR) spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used.
22 March 2021 | By Bruker Biospin Group
In this virtual roundtable, experts explore the uses of nuclear magnetic resonance (NMR) in the analysis of biologics and biosimilars and discuss how recent advances are changing the game.
Analogous to nuclear magnetic resonance spectroscopy, EPR measures electron spins, rather than those of atomic nuclei. Its investigative power has always offered unique insight, but it seems that only now is the technique coming into its own.
An important step in the research and development of biopharmaceuticals is to identify molecules with favourable physical and chemical stability profiles. Yongchao Su, Wei Xu and Bruce Yu discuss how solution, solid-state and benchtop nuclear magnetic resonance (NMR) methods can provide advanced biophysical characterisations of biological products.
Today’s biopharmaceutical developers need accurate and precise information at all stages of research and development in order to bring safe and effective therapies to patients. This in-depth focus features novel perspectives from industry experts that serve to illustrate which technologies and systems are benefitting this cause.
Researchers have developed an enhanced NMR method that could determine the structures of complex molecules much quicker than before...